Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H46N.Br |
Molecular Weight | 440.543 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1
InChI
InChIKey=DLNWMWYCSOQYSQ-UHFFFAOYSA-M
InChI=1S/C25H46N.BrH/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-20-23-26(2,3)24-25-21-18-17-19-22-25;/h17-19,21-22H,4-16,20,23-24H2,1-3H3;1H/q+1;/p-1
Cetalkonium chloride is a cationic quaternary ammonium surfactant, which is used for the treatment of mouth ulcers and sores (Bonjela trade name). It is also serves as an excipient for the purpose of long-term stabilization of ciclosporin ocular formulation, used in patients with dry eye syndrom (Ikervis trade name). The antibacterial properties of cetalkonium can be explained by its detergent character. Once applied, cetalkonium blocks the survival of biofilm forming bacterias.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | BONJELA Approved UseFor the relief of pain, discomfort and inflammation caused by common mouth ulcers, cold sores, denture and sore spots, as well as mouth ulcers, and sore spots due to orthodontic devices. To help to fight minor mouth infection and aid healing of sore spots and ulcers due to dentures and orthodontic devices. |
|||
Inactive ingredient | IKERVIS Approved UseTreatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes. Launch Date2015 |
|||
Primary | BONJELA Approved UseFor the relief of pain, discomfort and inflammation caused by common mouth ulcers, cold sores, denture and sore spots, as well as mouth ulcers, and sore spots due to orthodontic devices. To help to fight minor mouth infection and aid healing of sore spots and ulcers due to dentures and orthodontic devices. |
Doses
Dose | Population | Adverse events |
---|---|---|
0.1 % 1 times / day single, topical Studied dose Dose: 0.1 %, 1 times / day Route: topical Route: single Dose: 0.1 %, 1 times / day Sources: |
healthy, 28 to 55 years n = 8 Health Status: healthy Age Group: 28 to 55 years Sex: M+F Population Size: 8 Sources: |
Other AEs: Contact dermatitis... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Contact dermatitis | 37.5% | 0.1 % 1 times / day single, topical Studied dose Dose: 0.1 %, 1 times / day Route: topical Route: single Dose: 0.1 %, 1 times / day Sources: |
healthy, 28 to 55 years n = 8 Health Status: healthy Age Group: 28 to 55 years Sex: M+F Population Size: 8 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Occupational allergic contact dermatitis from alkylammonium amidobenzoate. | 2001 May-Jun |
|
Sulfentrazone adsorbed on micelle-montmorillonite complexes for slow release in soil. | 2003 May 21 |
|
Investigation of the effects of wall adsorption of the visualization agent on baseline noise characteristics for indirect UV detection in capillary electrophoresis. | 2003 Sep |
|
Influence of enhancers on the absorption and on the pharmacokinetics of cefodizime using in-vitro and in-vivo models. | 2004 Apr |
|
The synaptic vesicle proteome: a comparative study in membrane protein identification. | 2004 Oct |
|
On the adsorption of cetyldimethylbenzylammonium chloride at the mercury/electrolyte solution interface. | 2005 May 15 |
|
Identification of benzalkonium chloride in commercial grapefruit seed extracts. | 2005 Sep 21 |
|
Analysis of the synaptic vesicle proteome using three gel-based protein separation techniques. | 2006 Dec |
|
Measuring quaternary ammonium cleaning agents with ion selective electrodes. | 2006 Jun 16 |
|
Dechlorination of beta-methylallyl chloride by electrogenerated [Co(I)(bipyridine)3]+: an electrochemical study in the presence of cationic surfactants. | 2006 May 15 |
|
Synaptic vesicle proteins under conditions of rest and activation: analysis by 2-D difference gel electrophoresis. | 2006 Sep |
|
Characterization of multifunctional reverse micelles' interfaces using hemicyanines as molecular probes. II: Effect of the surfactant. | 2009 May 14 |
|
Cationic reverse micelles create water with super hydrogen-bond-donor capacity for enzymatic catalysis: hydrolysis of 2-naphthyl acetate by alpha-chymotrypsin. | 2010 Aug 2 |
|
[Optimization of benzalkonium chloride concentration in 0.0015% tafluprost ophthalmic solution from the points of ocular surface safety and preservative efficacy]. | 2010 Jun |
|
Synthesis, self-aggregation and biological properties of alkylphosphocholine and alkylphosphohomocholine derivatives of cetyltrimethylammonium bromide, cetylpyridinium bromide, benzalkonium bromide (C16) and benzethonium chloride. | 2013 Aug |
Patents
Sample Use Guides
Massage one centimetre of the topical formulation (Bonjela) onto the affected area (mouth ulcers and sores) and leave at least 30 min in case of denture sores. In dry eye disease, the recommended dose is one drop of the ocular formulation (Ikervis) once daily to be applied to the affected eye(s) at bedtime.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24001405
Corneal human cells were treated with 0.005% cetalkonium chloride cationic oil-inwater nanoemulsion for 30 min. The emulsion was able to increase the pace of healing, as measured by the reduction of the size of the scraped area.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
UHU0390Z3J
Created by
admin on Sat Dec 16 04:48:51 GMT 2023 , Edited by admin on Sat Dec 16 04:48:51 GMT 2023
|
PRIMARY | |||
|
DBSALT001775
Created by
admin on Sat Dec 16 04:48:51 GMT 2023 , Edited by admin on Sat Dec 16 04:48:51 GMT 2023
|
PRIMARY | |||
|
222-556-5
Created by
admin on Sat Dec 16 04:48:51 GMT 2023 , Edited by admin on Sat Dec 16 04:48:51 GMT 2023
|
PRIMARY | |||
|
DTXSID90956729
Created by
admin on Sat Dec 16 04:48:51 GMT 2023 , Edited by admin on Sat Dec 16 04:48:51 GMT 2023
|
PRIMARY | |||
|
263517
Created by
admin on Sat Dec 16 04:48:51 GMT 2023 , Edited by admin on Sat Dec 16 04:48:51 GMT 2023
|
PRIMARY | |||
|
165133
Created by
admin on Sat Dec 16 04:48:51 GMT 2023 , Edited by admin on Sat Dec 16 04:48:51 GMT 2023
|
PRIMARY | |||
|
3529-04-2
Created by
admin on Sat Dec 16 04:48:51 GMT 2023 , Edited by admin on Sat Dec 16 04:48:51 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD